In this issue:
Inflammatory biomarkers and risk of schizophrenia
Variability of regional brain structure in schizophrenia
ABT-126 in the treatment of cognitive impairment associated with schizophrenia
ASDs and antipsychotic treatment failure in early-onset psychosis
Cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia
Circadian rhythm disturbances predict worsened prognosis in adolescents at clinical-high risk for psychosis
Meta-analysis of PTSD symptoms and diagnoses in FEP
Remission and recovery from FEP
Trauma and psychotic experiences
Efficacy and safety of MIN-101: a new drug for the treatment of negative symptoms in schizophrenia
Please login below to download this issue (PDF)